CoChat

Imp2 regulates GBM progression by activating IGF2/PI3K/Akt pathway

Open access
Mu, Qingchun, Wang, Lijun, Yu, Fengbo, Gao, Haijun, Lei, Ting, Li, Peiwen, Liu, Pengfei, Zheng, Xu, Hu, Xitong, Chen, Yong, Jiang, Zhenfeng, Sayari, Arash J, Shen, Jia, Huang, Haiyan · 2015 · Cancer Biology & Therapy
Cited by 89

The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.

Abstract

Glioblastomas multiforme (GBM) are the most frequently occurring malignant brain cancers. Treatment for GBM consists of surgical resection and subsequent adjuvant radiation therapy and chemotherapy. Despite this, GBM patient survival is limited to 12-15 months, and researchers are continually trying to develop improved therapy options. Insulin-like growth factor 2 mRNA-binding protein 2 (Imp2) is known to be upregulated in many cancers and is known to regulate the signaling activity of insulin-like growth factor 2 (IGF2). However, relatively little is known about its role in malignant development of GBM. In this study, we first found Imp2 is upregulated in GBM tissues by using clinical samples and public database search. Studies with loss and gain of Imp2 expression in in vitro GBM cell culture system demonstrated the role of Imp2 in promoting GBM cell proliferation, migration, invasion and epithelial-to-mesenchymal transition (EMT). Additionally, our results show that Imp2 regulates the activity of IGF2, which further activates PI3K/Akt signaling, thereby to promote GBM malignancy. Inhibition of Imp2 was also found to sensitize GBM to temozolomide treatment. These observations add to the current knowledge of GBM biology, and may prove useful in development of more effective GBM therapy.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1080/15384047.2015.1019185

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 4 references

Cited by

See all 89

Metadata

Authors
Mu, Q., Wang, L., Yu, F., Gao, H., Lei, T., Li, P., Liu, P., Zheng, X., Hu, X., Chen, Y., Jiang, Z., Sayari, A. J., Shen, J., & Huang, H.
Venue
Cancer Biology & Therapy
Published
2015-02-26
Volume
16
Issue
4
Pages
623-633
ISSN
  • 1538-4047 (ISSN-L)
  • 1555-8576
OpenAlex
W1830662843
Cited by
89
References
4
FWCI
2.93
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Imp2 regulates GBM progression by activating IGF2/PI3K/Akt pathway. https://app.cochat.ai/papers/10.1080/15384047.2015.1019185
The paper
Mu, Q., Wang, L., Yu, F., Gao, H., Lei, T., Li, P., Liu, P., Zheng, X., Hu, X., Chen, Y., Jiang, Z., Sayari, A. J., Shen, J., & Huang, H. (2015). Imp2 regulates GBM progression by activating IGF2/PI3K/Akt pathway. Cancer Biology & Therapy. https://doi.org/10.1080/15384047.2015.1019185

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.